Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

被引：0
|
作者：
Prithviraj, Prashanth
McArthur, Grant A.
Atkinson, Victoria
Parente, Phillip
Andrews, Miles Cameron
Parakh, Sagun
Cebon, Jonathan S.
Klein, Oliver
机构：
[1] Austin Hlth, Med Oncol Unit, Heidelberg, Vic, Australia
[2] Peter MacCallum Canc Ctr, East Melbourne, Australia
[3] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia
[4] Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[5] Austin Hosp, Heidelberg, Vic, Australia
[6] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma
    Aya Moreno, F.
    Fernandez-Martinez, A.
    Gaba, L.
    Victoria, I.
    Arance Fernandez, A. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 6 - 6
  • [22] Anti-CTLA-4 Antibody Adjuvant Therapy in Melanoma
    Eggermont, Alexander M. M.
    Testori, Alessandro
    Maio, Michele
    Robert, Caroline
    SEMINARS IN ONCOLOGY, 2010, 37 (05) : 455 - 459
  • [23] Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence
    Cybulska-Stopa, Bozena
    Rogala, Pawel
    Czarnecka, Anna M.
    Lugowska, Iwona
    Teterycz, Pawel
    Galus, Lukasz
    Rajczykowski, Marcin
    Dawidowska, Anna
    Piejko, Karolina
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    ADVANCES IN MEDICAL SCIENCES, 2020, 65 (02): : 316 - 323
  • [24] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
    Kaehler, Katharina C.
    Hassel, Jessica C.
    Heinzerling, Lucie
    Loquai, Carmen
    Moessner, Rotraut
    Ugurel, Selma
    Zimmer, Lisa
    Gutzmer, Ralf
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
  • [25] Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
    Willsmore, Zena N.
    Coumbe, Ben G. T.
    Crescioli, Silvia
    Reci, Sara
    Gupta, Ayushi
    Harris, Robert J.
    Chenoweth, Alicia
    Chauhan, Jitesh
    Bax, Heather J.
    McCraw, Alexa
    Cheung, Anthony
    Osborn, Gabriel
    Hoffmann, Ricarda M.
    Nakamura, Mano
    Laddach, Roman
    Geh, Jenny L. C.
    MacKenzie-Ross, Alastair
    Healy, Ciaran
    Tsoka, Sophia
    Spicer, James F.
    Josephs, Debra H.
    Papa, Sophie
    Lacy, Katie E.
    Karagiannis, Sophia N.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (03) : 544 - 556
  • [26] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response
    Uzelac, Matthew
    Li, Wei Tse
    Li, Yuxiang
    Ongkeko, Weg M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B.
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Eastman, Lauren M.
    Maecker, Holden T.
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [28] Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
    Patel, Sandip P.
    Cano-Linson, Eleanor
    Chae, Young Kwang
    Schokrpur, Shiruyeh
    Lao, Christopher D.
    Powers, Benjamin C.
    Victor, Adrienne I.
    Onitilo, Adedayo A.
    Shin, Sarah
    Takebe, Naoko
    Threlkel, Sara
    Mcleod, Christine M.
    Chen, Helen X.
    Sharon, Elad
    Othus, Megan
    Ryan, Christopher W.
    Blanke, Charles D.
    Kurzrock, Razelle
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [29] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [30] Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
    Umeda, Yoshiyasu
    Yoshikawa, Shusuke
    Kiniwa, Yukiko
    Maekawa, Takeo
    Yamasaki, Osamu
    Isei, Taiki
    Matsushita, Shigeto
    Nomura, Motoo
    Nakai, Yasuo
    Fukushima, Satoshi
    Saito, Shintaro
    Takenouchi, Tatsuya
    Tanaka, Ryo
    Kato, Hiroshi
    Otsuka, Atsushi
    Matsuya, Taisuke
    Baba, Natsuki
    Nagase, Kotaro
    Inozume, Takashi
    Onuma, Takehiro
    Kuwatsuka, Yutaka
    Fujimoto, Noriki
    Kaneko, Takahide
    Onishi, Masazumi
    Namikawa, Kenjiro
    Yamazaki, Naoya
    Nakamura, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 361 - 372
12345